Repatha Only $49 million Worldwide for Q1 2017

Discussion in 'Amgen' started by anonymous, Apr 26, 2017 at 6:33 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Wow! Worldwide Sales of only $49million for Q1 2017! About 2 years post launch. That is way off pace for the blockbuster status Amgen promised. This product has been a dog since the start. Over priced, low level of additional benefit over a statin, low managed care access, and a labor intensive approval process. Tons of money spent on advertising, studies, and thought leaders to get on board the PCSK9 train. The heat is slowly being turned up on us. I am expecting that the pressure will become felt a lot more by summertime. I am disappointed that I came here. Terrible culture and unreasonable expectations. And please pull Corlanor! Most scripts are used off label and it is embarrassing to promote such a pathetic drug. I think it's time to polish up my resume.
     

  2. anonymous

    anonymous Guest

    let's break $50M by 4Q !! This is a rocket ship to the moon !!
     
  3. anonymous

    anonymous Guest

    What happened to all the talk about topping $10Billion? This drug is on pace for $200-$250 million this year. And this is with a price tag of 14k before rebates. Not a lot of uptake at all. Pretty sad if you ask me
     
  4. anonymous

    anonymous Guest

    This drug will be lucky to bring in $10B in it's lifetime let alone a year
     
  5. anonymous

    anonymous Guest

    Hey, Somxyl®, a topical agent to treat genital warts outsold Repatha in Q1.

    Perhaps we are in the wrong therapeutic areas here. Hell, wouldn't you rather sell a genital wart cream vs a complex MAB to treat high LDL?
    People need genital wart treatment much more than lowering LDL if can't take a generic statin.
    Think about it?
     
  6. anonymous

    anonymous Guest

    Welcome to Amgen, enjoy, the "Work streams"

     
  7. anonymous

    anonymous Guest

    Hahahaha...you made my day..the "work streams" that move at a glacial pace. The IC, Data, & culture workstreams have yielded great results..one year in and zero results..sorry forgot about the red, white, and blue name change...gotta give credit when its due....no sales.missing earnings...bill is coming due for the gigantic bcbu.
     
  8. anonymous

    anonymous Guest



    In the US we brought in just $33million. Embarrassing to say the least
     
  9. anonymous

    anonymous Guest

    ...now can we dump the contract sales team??o_O
     
  10. anonymous

    anonymous Guest

    The revenue from Repatha may actually drop in the coming quarters. Providers are fed up with the aggravating approval process. Also, many feel disappointed with the outcomes. They were hoping for much better results. Doctors were taking a leap of faith based on the hype from "thought leaders" like Steve Nissen at the Cleveland Clinic who was very vocal about the promise of PCSK9. Turns out Amgen paid him a fortune for his advocacy and help in studying Repatha. Wonder if he will continue down the path of touting the benefits of PCSK9s or if he will retreat with his money and slowly start to separate himself from Amgen.
     
  11. anonymous

    anonymous Guest

    At what point will Amgen cut the cord on Repatha? I'm guessing billions have been spent and nothing but a drop in the bucket in return. Hundreds of reps and middle management all making 6 figures when there is no return on investment. Not one of my district mates have sold anything close to what it costs to keep them in the field. The house of cards has to fall soon!
     
  12. anonymous

    anonymous Guest

    I heard talk that a sell off is on the table. We are looking for potential buyers. What is the right price tag for Repatha? We can't just give it away. But who is willing to pay $5 billion up front for the marketing rights, plus a lifetime royalty of a TBD amount? A lot of hype around this product. A lot of potential promise but we have yet to see the dream realized.
     
  13. anonymous

    anonymous Guest

    Repatha's fate is hinging on Enbrel Revenue. As long as Enbrel continues to bring the cash in Amgen can keep investing in Repatha. Once there is a dramatic reduction in revenue the heat will be turned up.
     
  14. anonymous

    anonymous Guest

    So why is it that almost every one of our drugs launched in the last 10 years is pathetic.
    Some only suck but then others are just downright embarrassing.

    Weren't we supposed to be launching a blockbuster every year?
     
  15. anonymous

    anonymous Guest

    Exelixis just reported sales of $ 69MM for 1Q for cabo. Perhaps Amgen should buy Exelixis for a real product with a strong launch.
     
  16. anonymous

    anonymous Guest

    After paying for sales reps/tv advertising and such....a big RED hole! Ya Dig!
     
  17. anonymous

    anonymous Guest

    How desperate have we become that we need to give a money back guarantee on our product. We never claimed to reduce heart attacks by 100%! I guess someone ran the numbers and feels that it is cheaper to do that than just lower the price tag. I am speechless!!
     
  18. anonymous

    anonymous Guest

    Only with Harvard Pilgrim. It's not like they have these agreements with other major plans.

    Reality is amgen is increasing rebates and making these agreements. You will only see it if the restrictions are relaxed.
     
  19. anonymous

    anonymous Guest

    The geniuses thought this would help our situation but it is not going to increase uptake. It is merely exposing us financially. We will end up paying them for every heart attack? Stock is starting to sink! Investors are seeing the icebergs.
     
  20. anonymous

    anonymous Guest

    Bottom line, the product sucks, the outcomes were not at ALL what was hoped for, and our company culture sucks. Next!!!!----->